MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma

Multiple myeloma (MM) remains largely incurable despite significant advances in biotherapy and chemotherapy. The development of drug resistance is a major problem in MM management. Macrophage migration inhibitory factor (MIF) expression was significantly higher in purified MM cells from relapsed pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Wang, Qiang, Zhao, Dongyu, Xian, Miao, Wang, Zhuo, Bi, Enguang, Su, Pan, Qian, Jianfei, Ma, Xingzhe, Yang, Maojie, Liu, Lintao, Zu, Youli, Pingali, Sai Ravi, Chen, Kaifu, Cai, Zhen, Yi, Qing
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7714094/
https://ncbi.nlm.nih.gov/pubmed/32582913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005795
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars